AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price ...

According to AbbVie, the company has "the stability ... The company headquarters are in Abbott Park, North Chicago, Illinois. Its current CEO is Miles White. Abbott is now comprised of four ...

NORTH CHICAGO, IL and SAN DIEGO, CA, USA I3, 2025 I AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical company with a market capitalization of $299 billion and annual revenue exceeding $55 billion, has announced the completion ...

screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has ...

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into a collaboration to ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...